A leading professor joins BT Pharma
A leading professor known for his work in oncology and r&d has started his presidency at the supervisory board at biopharma company BT Pharma.
A leading professor known for his work in oncology and r&d has started his presidency at the supervisory board at biopharma company BT Pharma.
Professor Thierry Hercend brings vast experience in management of biopharmaceutical development.
BT Pharma is involved in developing innovative immunotherapies to treat diseases and cancer caused by the human papilloma virus (HPV).
"Thierry Hercend has an outstanding international academic and industrial career. His appointment as president of our Supervisory Board will be of great value for BT Pharma as the company prepares the entry into clinical trials of ProCervix(R), our first candidate immunotherapeutic product," said chief executive officer Benedikt Timmerman.
Dr Thierry Hercend, MD & PhD, has more than 30 years of academic and pharmaceutical experience in various therapeutic areas such as oncology and inflammatory diseases.
"BT Pharma is at the forefront of HPV R&D," said Hercend. "I look forward to contributing to the company's success in this field."